Dr. Martin J. Murphy

Martin J. Murphy, Jr., PhD (New York University), DMedSc (Queen’s University-Belfast, h.c.), FASCO, is Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc.. He is also the Founding Executive The Oncologist, Stem Cells and Stem Cells Translational Medicine.
Dr. Murphy was founder and former Chief Executive Officer of the Hipple Cancer Research Center, co-founder of the Society for Translational Oncology. He serves the National Cancer Policy Forum of The Institute of Medicine of the United States National Academy of Sciences. He is a director of the Foundation for the National Institutes of Health. He is Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology. Dr. Murphy is a Fellow of the American Society of Clinical Oncology (FASCO, 2013). He has authored more than 150 peer-reviewed papers. From 2001 he works as the Chief Executive Officer of CEO Roundtable on Cancer which focuses on the workplace wellness culture and improvement of workplace health level to fight again chronic diseases including cancer.

Dr. WANG Chen

Dr. Wang Chen, chief physician, professor and Dr. of China Academy of Engineering.
He is an expert at respiratory medicine and critical care medicines. Dr. Wang Chen serves as the President of the Chinese Academy of Medical Sciences & Peking Union Medical College, the Director of the National Clinical Research Center for Respiratory Disease, the Director of the Respiratory Center of China- Japan Friendship Hospital, the Vice President of the Chinese Hospital Association, the Vice President of the Chinese Medical Doctor Association and the President of the Chinese Association of Respiratory Physicians of the Chinese Medical Doctor Association, the Honorary President of the Chinese Society of Respiratory Disease of the Chinese Medical Society, the Vice President of the China National Graduate Medical Education Expert Committee.
Dr. Wang Chen also serves as the Member of WHO Chronic Non-communicable Diseases Expert Committee, the Director of WHO Collaborating Center for Tobacco or Health, and the Honorary Fellow of the Department of Medicine at Imperial College, London. Dr. Wang is the editor-in-chief of Chinese Medical Journal and Clinical Respiratory Journal.

Mark Stevenson

Mark joined the company as Executive Vice President and President of the Life Sciences Solutions Group in 2014 through the acquisition of Life Technologies. In August 2017, he was promoted to Chief Operating Officer, with responsibility for all of Thermo Fisher’s life sciences related businesses as well as our R&D and digital strategies.

Dr. Douglas Lowy

Dr. Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. His laboratory, in close collaboration with John T. Schiller, Ph.D., was involved the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three U.S. Food and Drug Administration-approved HPV vaccines. For their pioneering work, Lowy and Schiller have received numerous honors, including the 2007 Federal Employee of the Year Award from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, the 2014 National Medal of Technology and Innovation from President Obama, and the 2017 Lasker DeBakey Clinical Medical Research Award.

Prof. LI Jin

Prof. Li Jin, chief physician, professor. He was graduated with bachelor’s degree from Southeast University, Nanjing, master’s degree in Gynecological Oncology and Ph.D. degree from the Second Military Medical University, Shanghai. He is also a postdoctor and visiting scholar to the Yale School of Medicine. Prof. Li also serves as the President of the Federation of Asian Clinical Oncology, President of the Chinese Society of Clinical Oncology, Secretary-General of Beijing Xisike Clinical Oncology Research Foundation, Vice President of the Experts Committee on Colorectal Cancer of Chinese Medical Doctor Association. Prof. Li is an expert at oncology (clinical practice and experimental research of oncology biological-chemical treatment), and is the editor-in-chief or member of editorial board for several academic journals. He has published nearly 100 papers as the first author or correspondent, and has led nearly 100 multi-centre clinical trials as principle investigator.

Dr. WANG Yu

Dr. Wang Yu is the Bachelor of Medicine, Peking Medical University, China; MD, Institute of Hepatology, Peking Medical University, China; PhD, Department of Preventive Biology, Jichi Medical School, Japan and PhD, Department of Preventive Biology, Jichi Medical School, Japan. During 2004 to 2017, Dr. Wang was the Director General, Chinese Center for Disease Control and Prevention, Dr. WANG is majoring in liver diseases (internal medicine) and specialized in viral immunology, molecular virology (doctorate supervisor).

Prof. ZHAN Qimin

Prof. Zhan Qimin, Academician of China Academy of Engineering, Member of the Peking University CPC Standing Committee, Vice-President of Peking University, President of Peking University Health Science Center (PKUHSC), and Director of State Key Laboratory of Molecular Oncology.

Tony Acciarito

Tony Acciarito has been President of Thermo Fisher Scientific China since January 2018. Prior to this role, Tony was Vice President and General Manager of South Korea since January 2014, and was responsible for leading employees across multiple divisions in addition to developing and implementing a long-term strategic plan that led to rapid business growth in South Korea.

Dr. Steffan Ho

Steffan Ho is currently Vice President and Head of Translational Oncology in the Global Product Development organization at Pfizer. As a board-certified pathologist and principal research investigator with over 20 years of clinical, academic and industry experience, Dr. Ho brings together an understanding of clinical diagnostics, human cancer, tumor biology, precision medicine, technology platforms, and drug development.

Dr. Corina Shtir

Dr. Shtir joined Thermo Fisher Scientific in 2013. Her expertise spans many areas, enabling her to take an integrative approach to driving population-scale programs for both rare and complex disorders. Her specialties include population genetics and biostatistics (PhD), statistical genetics, mathematics, epidemiology, and computational biology. She directs precision medicine programs integrating the omics spectrum, big data, regenerative medicine and new bio-pharma ventures, to revolutionize the way we prevent, detect and treat disease.

Dr. Joseph Eid

Dr. Joseph Eid is a physician, board certified in Medical Oncology, Hematology, and Internal Medicine. He joined BMS in 2017 as Senior Vice President and Head of Medical.
Before joining BMS, Joe worked at Merck in Oncology Clinical Research, and in this capacity he was the team leader for Pembrolizumab (anti-PD-1 antibody) from first in man trial leading to registration. Prior to joining Merck, Joe was at Roche Pharmaceuticals in Oncology Clinical Research.

Dr. Matthew D. Brown

Matthew Brown has been the Director of the NIH National Cancer Institute Beijing office since September 2016. Prior to this, he was a senior advisor to the HHS Assistant Secretary for Global Affairs. He has held positions as the Department of Defense HIV/AIDS Prevention Program, Deputy Director for the CDC Offices in China and Cote d’Ivoire, and Country Director for the CDC Office in Haiti.

Prof. LIU Yuanli

Prof. Liu, doctoral advisor, professor of Health Policies and Administrations, and the President of Chinese Academy of Medical Sciences and Peking Union Medical College. Prof. Liu is a guest expert of Thousand Talents Program hosted by the Organization Department of the CPC Central Committee, and the President of the Chinese Aging Well Association.

Prof. DONG Zigang

Prof. Dong is the Executive Director, Hormel/Knowlton Professor, and I. J. Holton Professor of The Hormel Institute, University of Minnesota (UMN). In 2006, he received the UMN McKnight Presidential Professorship in Cancer Prevention, one of the highest honors bestowed by the University. He is one of a very few professors holding three endowed professorships simultaneously at UMN. Dr. Dong is a world leader in cancer prevention and molecular carcinogenesis.

Prof. QIAO Jie

Prof. Qiao is the commissioner of the Chinese Medical Doctor Association and the 3rd session of Chinese Society of Reproductive Medicine. As the chief scientist of "Major Procreation and Development Projects" of the Ministry of Science and Technology, specially-appointed professor of the Chang Jiang Scholar Program of the Ministry of Education, chief expert of the "germinal development" of the innovation research group of the National Natural Science Foundation of China, Seth has always been engaged in clinical and basic research of obstetrics and gynecology and reproductive health.

Prof. LIAO Can

Prof. Liao is the chief physician of obstetrics and gynecology, doctoral tutor; winner of the Second Chinese Physician Prize, State Council Expert for Special Allowance, excellent expert of Guangzhou City. Now serving as Deputy Director of Guangzhou Women and Children’s Medical Center and other positions. Conferred with 16 scientific and technological progress awards at levels of state, province and municipal city.

Prof. QIN Jun

Prof. Qin is the famous scientist and biological mass spectrometry biological chemist, Professor of Baylor College of Medicine, director of the Molecular Research and Pathway Discovery Center, one of the foreign scholars from the "1000plan", Beijing overseas talent aggregation project, and the Military Medical Science Academy of the PLA Institute of radiation medicine researcher, doctoral tutor, director of Beijing proteome research center, network and signal transduction project leader, vice director of the State Key Laboratory of proteomics.

Prof. Bruce Ling

Dr. Ling earned his PhD in Biological Chemistry in UCLA and completed his postdoctoral training in molecular immunology and computer science.
He was a Incyte scientist in the United States as the head of algorithm project, director of research and development of DoubleTwist, Tularik, and Amgen.
Dr. Ling is now a Professor of Stanford University as the director of translational medicine lab in Stanford Medical School. He has earned a lot of awards like the Spark Innovation Awards, first prize of Stanford University Cardiovascular Research Institute and so on.
He is also co-founders of successful biotech companies in silicon valley like Carmenta Bioscience, big data medical systems for business (HBI Solutions Inc.) and high throughput medical data production and AI analysis company (mProbe, Inc.).

Dr. Todd Hembrough

The President of Proteomics for NantOmics, Todd oversees R&D, operations and the clinical proteomics laboratory. Prior to NantOmics, Todd held roles of increasing responsibility at OncoPlex Diagnostics and Expression Pathology (OPDx), culminating in holding the Chief Scientific Officer and Head of R&D. Prior to OPDx, Todd was a member and leader in the Translational Oncology team at EntreMed. Todd has more than twenty publications and over twenty five patents either issued or pending for technologies he has developed.

William Liang

William Liang joined AstraZeneca China in June 2014 as Vice President, Oncology BU. Under his leadership, the team keeps optimizing TA strategies, steadily promote a patient-centric business model integrating diagnosis and treatment and ensure AstraZeneca oncology business continues to lead the market. Before joining AstraZeneca, he was Vice President of Oncology at Bristol-Myers Squibb in China, where he helped expand the oncology sales team and achieve significant overall growth. Prior to that, he held different marketing and business positions at Abbott and Roche. From 2009 to 2011, William was Business Unit Leader of Oncology at Roche Hong Kong.

Prof. Andrew Kasarskis

In addition to Director, Icahn Institute for Genomics and Multiscale Biology, Prof. Kasarskis is Interim Chair, Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. His research is focused on developing and applying technology to biomedical problems including pathogen surveillance, host response to viral infection, inflammatory bowel disease, sleep, and learning from observational data. Prior to Mount Sinai he led teams at Pacific Biosciences, Sage Bionetworks, and Merck and has almost two decades of experience managing research and technology development projects in software engineering, data science, drug development, human and mouse genetics, and other applications of biological research.

Prof. Catherine Wong

Prof. Catherine Wong is currently Director of Precision Medicine Multiomics Research Center under Peking University Health Science Center. She was designated as "Introduced Prominent Technical Talents" of Chinese Academy of Sciences in 2014. She was formerly a Principal Scientist in the Yeast Resources Center under National Center for Research Resources (NCRR) and Center for Physiological Proteomics at The Scripps Research Institute, as well as Director of Mass Spectrometry Department and subsequently assistant to Center Director, National Center for Protein Science, Chinese Academy of Sciences.

Dr. CAI Long

Cai Long is the Professor in engineer, Professor in finance; Board chairman and general manager of Nanjing Yang Zi State-Owned Investment Group; Director of National Center for Health Data (Nanjing); Vice-chairman of Jiangsu Institute of International Finance; Outstanding science and technology leader of 333 high level talents training project in Jiangsu; International expert in urban water and sanitation of United Nations Human Settlements Program; Guest professor of National mayor Training Center; Adjunct professor of Nanjing University.

Prof. Nam Do Hyun

Nam Do Hyun is the Professor of Department of Neurosurgery, Samsung Medical Center; Sungkyunkwan University School of Medicine; Director, Samsung Institute for Refractory Cancer Research; Director, Center for Experimental Therapeutics of Samsung Cancer Research Institute; Director, Research Center of Future Medicine. Participation in Academic Societies and Research, Member of Korean Neurosurgical Society, Member of Korean Brain Tumor Society, Member of American Association of Neurological Surgeons, Member of American Association of Cancer Research.

Prof. Timothy Triche

Timothy Triche is the former Chair of Pathology at Children’s Hospital Los Angeles, University of Southern California, and the founding director of the Center for Personalized Medicine at CHLA. Dr. Triche came to CHLA from the National Cancer Institute where he developed several molecular diagnostic assays for childhood cancer. He and his lab members were among the first to identify unique gene translocations in childhood cancer, as well as PCR assays for gene mutations and FISH assays for gene amplification, among others. In addition to this clinical work, his research lab has discovered key regulatory RNA transcripts unique to specific childhood cancer types and their biologic behavior.

Prof. ZHAO Yangbing

Prof. Zhao is Associate Professor and the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an M.D. and Ph.D. in Immunology from the Third Medical University in Chongqing, China. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as the Director of TCEL. Dr. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work, has directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing.

Prof. QIAO Youlin

Prof. Qiao is the director of Epidemiological Research Office, Cancer Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College, researcher/professor, doctorate supervisor and postdoctoral supervisor, concurrently the Deputy Secretary-General of Cancer Foundation of China and director of its Foreign Affairs Department, the commissioner of China Anti-Cancer Association Cancer Epidemiology Committee, the Secretary General of APOCP and other titles of many other international associations.

Dr. Alan Sachs

Dr. Sachs leads efforts to maximize growth through investments in R&D that help customers accelerate life sciences research, solve complex analytical challenges,improve patient diagnostics and increase laboratory productivity. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute. Dr. Sachs graduated with an M.D. and Ph. D. from Stanford Medical School.

Prof. LI Yixue

Professor of CAS-MPG Partner Institute of Computational Biology, Chinese Academy of Sciences, Director of Biomedical Big Data Center, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Director of Shanghai Center for Bioinformation Technology, former Director of Department of Bioinformatics and Biostatistics, Shanghai Jiaotong University. Dr. Li has published more than 300 peer review journal papers in various international scientific journals. Yixue Li’s articles have been cited more than 12500 times in other scientific papers.

Dr. YANG Hongwei

Dr. Yang Hongwei is Deputy Director General of China National Health Development Research Center (NHDRC) since September 2013. Prior to that, he had worked as a program officer in WHO Representative Office in China for more than 6 years before he joined the Center. He was also worked as Director of General Office in Foreign Loan Office, Ministry of Health, P.R.China. Dr. Yang graduated from the School of Public Planning and Development in the University of Southern California, US in September 1999 and was awarded the degree on Master of Public Policy and Management.

Dr. Frank Su

Founding Partner of Redhill Capital; Venture Partner of Share Capital/ Healthcare Fund IC Member, Tutor of several healthcare incubators and Entrepreneurship Camp. Eighteen years working experiences in medical industry; Frank succeed in growing a startup to a major player as Co-Founder of Techlink Medical. After transferred to VC role, Frank and his fund focused on healthcare early stage investment. Among over 52 medical portfolio companies, many grow from rookie to famous corporation，like BGI, MeiNian Healthcare ,BuChang Pharmaceutical, Genetron Health, Medprint etc.

Dr. Seth Sadis

Seth leads a team of Software and Test Engineers, Bioinformaticists and Translational Oncology scientists to develop tests and informatics workflows on the Ion Torrent next generation sequencing platform. Seth's team led the development of the Oncomine™ Assays that are now used globally for targeted profiling of cancer. Seth earned a Ph.D. in Biochemistry from the University of Connecticut and completed a postdoctoral fellowship at Harvard Medical School. Seth's professional career includes 15 years in biopharma spanning oncology drug discovery and translational medicine through clinical development and diagnostics.